Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Regeneron Pharmaceuticals, the $5.9 billion Tarrytown, N.Y.-based biotech firm, and gene therapy upstart Bluebird Bio will team up to invent genetically modified white blood cells that can attack cancer -- a technology known as CAR-T cells. The collaboration will make use of Regeneron's technologies for using mice to create human antibodies and receptors for T cells, a type of white blood cell.
https://www.forbes.com/sites/matthewherper/2018/08/06/regeneron-and-bluebird-team-invent-new-cell-therapies-for-cancer/

David Bromberg Quintet

Born in Philadelphia in 1945 and raised in Tarrytown, NY, "as a kid I listened to rock 'n' roll and whatever else was on the radio," says Bromberg. "I discovered Pete Seeger and The Weavers and, through them, Reverend Gary Davis.
https://chicago.thelocaltourist.com/event/david-bromberg-quintet?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+TheLocalTourist+%28The+Local+Tourist+Chicago%3A+Your+online+guide+to+your+offline+life%29

Rounds Report: Progenics Rallied Subsequent To The Azedra Approval

... the stock appreciated by $0.75 to conclude the trading session at $9.18 for over +8.9% profits. Headquartered in Tarrytown, NY, Progenics is a specialist in the innovation and commercialization of targeted radiopharmaceuticals for the detection and ...
https://seekingalpha.com/article/4194998-rounds-report-progenics-rallied-subsequent-azedra-approval?source=partner_topix

UPDATE 1-Regeneron posts quarterly profit beat, strongly backs Eylea's future

FILE PHOTO: A robotic DNA sample automation machine works on DNA samples at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York, U.S., March 24, 2015. REUTERS/Mike Segar/File Photo However, Regeneron still sees a "large opportunity" for Eylea to treat diabetic eye disease and the drugmaker will focus on expanding its label and marketing it with a new TV campaign, company executives said on a conference call with analysts.
https://www.reuters.com/article/us-regeneron-pharms-results/regeneron-posts-quarterly-profit-beat-strongly-backs-eyleas-future-idUSKBN1KN1I3

Regeneron profit beats expectations on sales of eczema drug

FILE PHOTO: A robotic DNA sample automation machine works on DNA samples at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York, U.S., March 24, 2015. REUTERS/Mike Segar/File Photo U.S. sales of Regeneron's flagship eye drug, Eylea, increased 8 pct to $992 million in the second quarter, but missed estimates of $1 billion, according to brokerage Piper Jaffray.
https://www.reuters.com/article/us-regeneron-pharms-results/regeneron-profit-beats-expectations-on-sales-of-eczema-drug-idUSKBN1KN1I3

Prestige Brands: Fiscal 1Q Earnings Snapshot

The Tarrytown, New York-based company said it had profit of 65 cents per share. Earnings, adjusted for non-recurring costs, were 68 cents per share.
http://www.hastingstribune.com/prestige-brands-fiscal-q-earnings-snapshot/article_268e1725-3ed3-5244-b3e0-70aba04f4f1f.html

Prestige Brands: Fiscal 1Q Earnings Snapshot

The Tarrytown, New York -based company said it had profit of 65 cents per share. Earnings, adjusted for non-recurring costs, were 68 cents per share.
https://www.usnews.com/news/best-states/new-york/articles/2018-08-02/prestige-brands-fiscal-1q-earnings-snapshot